Moderna: Revenue Surprise and Cancer Pipeline – The Starting Signal for Re-evaluation has Been Given!

Moderna defies the swan song of the post-Covid era and significantly exceeds Wall Street expectations with revenue of $678 million in Q4. The biotech company from Cambridge, Massachusetts, was well above the average analyst estimates of $626 million. Following the massive drop in demand for Covid vaccines, the company is under pressure to prove the long-term viability of its mRNA technology through new products. The management is responding to the financial challenges with a strict growth focus and reaffirmed its expectation of a 10% revenue increase...